Early Relapse Signals High-Risk Primary Refractory LBCL
A secondary analysis of a phase 3 trial suggests that patients with relapse within 3 months of treatment or persistent disease represent a distinct high-risk group.
Medscape Medical News
source https://www.medscape.com/viewarticle/early-relapse-signals-high-risk-primary-refractory-lbcl-2026a1000as0?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/early-relapse-signals-high-risk-primary-refractory-lbcl-2026a1000as0?src=rss
Comments
Post a Comment